French Pharmacists Want Right to Publicity

12 December 1994

Some 10 groupings of French pharmacists are opposing their official regulatory body, the OP, over the right to use publicity and promotional material to combat competition from the major chains such as Leclerc and Euro-Sante-Beaute.

The new regulatory code covering pharmacy operations replaces a 40-year-old regulation, and is now being examined by the State Council before being promulgated as a legal decree.

The president of one of the opposing groups, Joseph Benwaiche of Plus Pharmacie, says the text has been drawn up without consultation, and effectively condemns pharmacies to death, especially as it reaffirms restrictions on group activity in terms of publicity and promotion. Article 58 states that "no publicity can be undertaken by an association, a group or a network of pharmacists."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight